Atorvastatin Calcium
Product Images NDC 45865-726

5 FDA label images from Medsource Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 45865-726). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (726)

Pdp (726)
Atorvastatin Calcium Tablets 20 mg label for a generic version of Lipitor by Medsource Pharmaceuticals. The label indicates film-coated, white, round tablets, lot number 45865-0726-49, with warnings to avoid grapefruit and alcohol. Dosage instructions say to take the tablets daily or as directed by a physician. The product NDC is 45865-0726.*
FDA Label Image

Chemical Structure (Atorvastatin Calcium Tablets 1)

Chemical Structure (Atorvastatin Calcium Tablets 1)
Chemical structure of Atorvastatin Calcium, showing its molecular components including calcium ions and hydration. The diagram depicts the arrangement of atoms and bonds for this active pharmaceutical ingredient.*
FDA Label Image

Figure 1 (Atorvastatin Calcium Tablets 2)

Figure 1 (Atorvastatin Calcium Tablets 2)
A line graph showing cumulative incidence percentage over time in years for Atorvastatin versus Placebo groups. Atorvastatin is represented by a solid line with a lower cumulative incidence compared to the placebo's dashed line. The graph includes a hazard ratio (HR=0.64) with confidence intervals and a p-value (0.0005) indicating statistical significance.*
FDA Label Image

Figure 2 (Atorvastatin Calcium Tablets 3)

Figure 2 (Atorvastatin Calcium Tablets 3)
A line graph showing cumulative hazard percentage over time to first primary endpoint up to four years of follow-up. It compares Atorvastatin treatment (solid line) versus placebo (dashed line), illustrating lower cumulative hazard with Atorvastatin. The graph includes a hazard ratio (HR) of 0.63 with confidence interval and p-value (0.001).*
FDA Label Image

Figure 3 (Atorvastatin Calcium Tablets 4)

Figure 3 (Atorvastatin Calcium Tablets 4)
A line graph comparing the percentage of subjects experiencing an event over time between Atorvastatin 10 mg and Atorvastatin 80 mg groups. The x-axis represents time to first major cardiovascular endpoint in years, and the y-axis shows the percentage of subjects experiencing the event. The graph includes hazard ratio and p-value data for the comparison.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.